Eli Lilly said preliminary data from a late-stage study showed its weight-loss drug significantly reduced the risk of progression to type 2 diabetes among adults with prediabetes and obesity or overweight.
Related Posts
For EV Startups, Things Are Going From Bad to Worse
Makers and suppliers of electric cars are dealing with diminishing cash, uneven sales and the prospects of an unfriendly Trump administration.
GM Is Cutting More Than 1,000 Employees Globally
The move affects the company’s software and services division.
Shell Launches $3.5 Billion Buyback After Earnings Beat
Shell said its second-quarter earnings came in ahead of expectations, and that it would buy back $3.5 billion of shares this quarter.